Moleculin Biotech (MBRX) Stock Price, News & Analysis

Company Overview

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development. WP1066 is an immunotherapeutic compound designed to inhibit the STAT3 signaling pathway, which is implicated in the growth and survival of certain brain tumors and other malignancies. Annamycin is an anthracycline derivative engineered to overcome resistance mechanisms in acute myeloid leukemia (AML) with the goal of improving safety and efficacy. In addition, Moleculin is advancing WP1220, a broad-spectrum antiviral candidate targeting poxviruses and coronaviruses through inhibition of viral replication.

Headquartered in Houston, Texas, Moleculin Biotech collaborates with academic institutions and contract research organizations to conduct its preclinical and clinical studies. The company’s development programs include Phase 1 and Phase 2 clinical trials in the United States, with plans to initiate additional studies in international markets as regulatory approvals are secured. Such partnerships and trial sites enable Moleculin to advance its candidates efficiently through the clinical development pathway.

Founded in 2012, Moleculin Biotech is led by Walter Klemp, President and Chief Executive Officer, a veteran in the biotech industry with experience in drug development and corporate strategy. Under his leadership, the company continues to expand its research capabilities and global trial network, aiming to bring its innovative therapies to patients with critical oncological and viral diseases.

Key Stats

• Today's Range: $2.61 to $2.94
• 50-Day Range: $2.09 to $3.12
• 52-Week Range: $1.79 to $24.00
• Volume: 897,702 shs
• Average Volume: 285,430 shs
• Market Capitalization: $15.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.00
• Consensus Rating: Hold

Moleculin Biotech Stock Analysis - MarketRank™

Moleculin Biotech scored higher than 40% of companies evaluated by MarketBeat, and ranked 605th out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Moleculin Biotech has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Moleculin Biotech has a consensus price target of $22.00, representing about 650.9% upside from its current price of $2.93.

Amount of Analyst Coverage

Moleculin Biotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Moleculin Biotech are expected to grow in the coming year, from ($5.10) to ($4.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Moleculin Biotech is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Moleculin Biotech is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Moleculin Biotech has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.71% of the float of Moleculin Biotech has been sold short.

Short Interest Ratio / Days to Cover

Moleculin Biotech has a short interest ratio ("days to cover") of 3.15, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Moleculin Biotech has recently increased by 57.06%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Moleculin Biotech does not currently pay a dividend.

Dividend Growth

Moleculin Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 4 people have searched for MBRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Moleculin Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Moleculin Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.10% of the stock of Moleculin Biotech is held by insiders.

Percentage Held by Institutions

15.52% of the stock of Moleculin Biotech is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 6/24/2026
• Next Earnings (Estimated): 8/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MBRX
• CIK: 1659617
• Web: www.moleculin.com
• Phone: (713) 300-5160
• Fax: N/A
• Employees: 20
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Moleculin Biotech: $22.00
• High Price Target: $22.00
• Low Price Target: $22.00
• Potential Upside/Downside: +650.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($17.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.56 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -70.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.38
• Quick Ratio: 1.38

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.69 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 5,340,000
• Free Float: 5,277,000
• Market Cap: $15.65 million
• Optionable: Not Optionable
• Beta: 1.77